[HTML][HTML] Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection
R Garcia-Carbonero, R Salazar, I Duran… - … for immunotherapy of …, 2017 - Springer
Abstract Background Enadenotucirev (formerly ColoAd1) is a tumor-selective chimeric
adenovirus with demonstrated preclinical activity. This phase 1 Mechanism of Action study …
adenovirus with demonstrated preclinical activity. This phase 1 Mechanism of Action study …
[HTML][HTML] A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)
JP Machiels, R Salazar, S Rottey, I Duran… - … for immunotherapy of …, 2019 - Springer
Background Enadenotucirev is a chimeric adenovirus with demonstrated preclinical tumor-
selective cytotoxicity and a short half-life. Further clinical mechanism of action data showed …
selective cytotoxicity and a short half-life. Further clinical mechanism of action data showed …
[PDF][PDF] Interactions of phospholipids with the potassium channel KcsA
IM Williamson, SJ Alvis, JM East, AG Lee - Biophysical Journal, 2002 - cell.com
The potassium channel KcsA from Streptomyces lividans has been reconstituted into
bilayers of phosphatidylcholines and fluorescence spectroscopy has been used to …
bilayers of phosphatidylcholines and fluorescence spectroscopy has been used to …
[HTML][HTML] The interfacial lipid binding site on the potassium channel KcsA is specific for anionic phospholipids
Lipid binding to the potassium channel KcsA from Streptomyces lividans has been studied
using quenching of the fluorescence of Trp residues by brominated phospholipids. It is …
using quenching of the fluorescence of Trp residues by brominated phospholipids. It is …
[HTML][HTML] Preclinical safety studies of enadenotucirev, a chimeric group B human-specific oncolytic adenovirus
S Illingworth, Y Di, M Bauzon, J Lei, MR Duffy… - Molecular Therapy …, 2017 - cell.com
Enadenotucirev is an oncolytic group B adenovirus identified by a process of bio-selection
for the ability to selectively propagate in and rapidly kill carcinoma cells. It is resistant to …
for the ability to selectively propagate in and rapidly kill carcinoma cells. It is resistant to …
[HTML][HTML] Interactions of anionic phospholipids and phosphatidylethanolamine with the potassium channel KcsA
SJ Alvis, IM Williamson, JM East, AG Lee - Biophysical journal, 2003 - cell.com
Fluorescence quenching methods have been used to study interactions of anionic
phospholipids with the potassium channel KcsA from Streptomyces lividans. Quenching of …
phospholipids with the potassium channel KcsA from Streptomyces lividans. Quenching of …
A phase 1 mechanism of action study of intratumoral or intravenous administration of enadenotucirev, an oncolytic Ad11/Ad3 chimeric group B adenovirus in colon …
R Garcia-Carbonero, M Gil-Martin, E Calvo, S Prados… - 2014 - ascopubs.org
TPS3112 Background: To date convincing clinical success with oncolytic viruses tends to be
associated with intra-tumoral (IT) administration and evidence for successful systemic …
associated with intra-tumoral (IT) administration and evidence for successful systemic …
A phase I study of pembrolizumab in combination with enadenotucirev (EnAd)(SPICE) in subjects with metastatic or advanced carcinoma.
WA Harb, V Cerec, H McElwaine-Johnn, B Champion… - 2016 - ascopubs.org
TPS3112 Background: EnAd is a tumor-selective chimeric Ad11/Ad3 group B oncolytic
adenovirus developed using a process of directed evolution. Phase I clinical studies have …
adenovirus developed using a process of directed evolution. Phase I clinical studies have …
A phase I/II study of enadenotucirev, a chimeric Ad11/Ad3 oncolytic group B adenovirus, administered intraperitoneally (IP) in platinum-resistant epithelial ovarian …
IA McNeish, A Michael, GC Jayson, RM Glasspool… - 2016 - ascopubs.org
5543 Background: Enadenotucirev (EnAd) is a tumor selective Ad11/Ad3 group B
adenovirus that has demonstrated preclinical activity in a model of platinum-resistant …
adenovirus that has demonstrated preclinical activity in a model of platinum-resistant …
A phase I study of enadenotucirev (EnAd), an oncolytic Ad11/Ad3 chimeric group B adenovirus, in combination with nivolumab in tumors of epithelial origin.
WA Harb, LS Rosen, D Wang, M Fakih, D Mahadevan… - 2017 - ascopubs.org
TPS3115 Background: EnAd is a tumor-selective chimeric Ad11/Ad3 group B oncolytic
adenovirus developed using directed evolution. Phase I clinical studies have identified a …
adenovirus developed using directed evolution. Phase I clinical studies have identified a …